Expert: Combination of Lenvatinib, Pembrolizumab Outperformed Sunitinib in the Treatment of Advanced RCC

Viktor Grunwald, MD, PhD, discusses the post-hoc analysis of the phase 3 CLEAR trial investigating the combination treatment in the first-line setting for advanced renal cell carcinoma.

Related Keywords

Viktor Grunwald ,Axel Kock ,Pfizer ,European Society Of Medical Oncology ,University Hospital Essen ,Pharmacy Times ,Interdisciplinary Genitourinary Oncology ,Medical Oncology ,